



Cervix cancer committee

SENTICOL III: International prospective validation trial of sentinel node biopsy in cervical cancer

A Gynecologic Cancer interGroup (GCIG) trial, lead by the GINECO

F Lecuru, N Abu-Rustum, P Mathevet, M Plante.

**GYNECOLOGIC
CANCER INTERGROUP**

An Organization of International Cooperative
Groups for Clinical Trials in Gynecologic Cancers



Nodal involvement is the most important prognostic factor for early cervical cancer



Low tumor burden

<25% N+ patients
only 1 N+ in 50% cases
22% <2mm



Complications of systematic lymphadenectomy



Up 10% nodal recurrences
in « pN0 » patients





Advances and Concepts in Cervical Cancer Trials A Road Map for the Future

Satoru Sagae, MD,* Bralley J. Monk, MD,† Eric Pujade-Lauraine, MD,‡ David K. Gaffney, MD,§
Kailash Narayan, MD,|| Sang Young Ryu, MD,¶ Mary McCormack, PhD, FRCR,# Marie Plante, MD,**
Antonio Casado, MD,†† Alexander Reuss, MSc,‡‡ Adriana Chávez-Blanco, DVM,§§
Henry Kitchener, MD,|||| Byung-Ho Nam, PhD,¶¶ Anuja Jhingran, MD,## Sarah Temkin, MD,***
Linda Mileshtin, MD,||| Els Berns, MD,††† Stacy Scholl, MD,‡‡‡ Corinne Doll, MD,§§§
Nadeem R. Abu-Rustum, MD,||||| Fabrice Lecuru, MD,¶¶¶ William Small Jr, MD,###
and On behalf of the participants of the Gynecologic Cancer InterGroup
Cervix Cancer brainstorming day

Objective: Cervical cancer is responsible for more than a quarter of a million deaths globally each year, mostly in developing countries, making therapeutic advances in all health care settings a top priority. The Gynecologic Cancer InterGroup (GCIg) is a worldwide collaboration of leading national research groups that develops and promotes multinational trials in gynecologic cancer. In recognition of the pressing need for action, the GCIg convened an international meeting with expert representation from the GCIg groups and selected large sites in low- and middle-income countries.

Methods: The focus was to develop a consensus on several concepts for future clinical trials, which would be developed and promoted by the GCIg and launched with major international participation. The first half of the meeting was devoted to a resume of the current state of the knowledge and identifying the gaps in need of new evidence, validating control arms for present and future clinical trials and identifying national and international barriers for studies of cervix cancers. The second half of the meeting was concerned with achieving consensus on a path forward.

*Department of Gynecologic Oncology, Sapporo West Kojinkai Clinic, Sapporo, Japan; †University of Arizona Cancer Center-Phoenix, Creighton University School of Medicine at St Joseph's Hospital and Medical Center Phoenix, AZ; ‡Hôtel-Dieu, AP-HP, Université Paris Descartes, Paris, France; §Department of Radiation Oncology, Huntsman Cancer Hospital, University of Utah Health Care, Salt Lake City, UT; ¶Division of Radiation Oncology, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia; ††Department of Surgery, Chonnam National University Medical School, Gwangju, South Korea; †††Department of Oncology, University College Hospital London, London, United Kingdom; **Division of Gynecologic Oncology, Centre Hospitalier Universitaire de Québec, Québec, Québec, Canada; †††Department of Medical Oncology, Hospital Clínico San Carlos, Madrid, Spain; ††††Coordinating Center for Clinical Trials of the Philipps-University of Marburg, Marburg, Germany; †††††GCIgCOM Grupo Mexicano de Investigaciones Cáncer de Ovario/Tumores Ginecológicos, A.C. México City, México; ††††††Institute of Cancer Sciences, University of

Manchester, St Mary's Hospital, Manchester, United Kingdom; ††††††Biotechnology Research Division, National Fisheries Research and Development Institute, Busan, South Korea; ††††††Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; ††††††Community Oncology and Prevention Trials Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD; ††††††Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; ††††††Médical-Spécialiste en Oncologie, Institut Curie, Paris, France; ††††††Division of Radiation Oncology, Department Oncology, University of Calgary, Calgary, Alberta, Canada; ††††††Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY; ††††††Chirurgie Gynécologique Gynécologique et de Sein, Université Paris Descartes, Sorbonne Paris Cité, Paris, France; and ††††††Department of Radiation Oncology, Stish School of Medicine Loyola University, Chicago, IL.

Address correspondence and reprint requests to: Satoru Sagae, MD, PhD, Department of Gynecologic Oncology, Sapporo West Kojinkai Clinic, Miyazawa 1-1-1-30 Nishi-ku, Sapporo 063-0051, Japan. Email: s_sagae@kojinkai.or.jp

The authors declare no conflicts of interest.

Presented at the Gynecologic Cancer InterGroup Cervix Cancer brainstorming day, Melbourne, Australia, November 6, 2014.

Copyright © 2015 by IGCS and ESGO
ISSN: 1048-891X
DOI: 10.1097/IGC.0000000000000587


Sentinel Node Biopsy – early cervical cancer



- ❖ Feasibility
- ❖ Reproducibility
- ❖ Diagnostic accuracy *
- ❖ Anatomical information
- ❖ Histological information (prognosis?)
- ❖ Reduced morbidity ?
- ❖ Similar prognosis ?

*: high NPV in case of bilateral detection

Altgassen G & al 2008
Lécuru F & al 2011
Plante M, Roy M & al 2011
Cormier B & al 2011



Objectives

❖ Main objective:

« co-primary » disease free survival and health related quality of life


- non-inferiority of SLN biopsy vs lymphadenectomy for DFS
- superiority of SLN biopsy for QoL

The hypothesis is that SLN biopsy alone provides similar survival and better quality of life.

❖ Secondary objectives:

- ❖ - **Outcome of pN1 patients according to the size of metastasis and treatment (isolated tumor cells and micrometastases),**
- ❖ - **Evaluation of mapping with indocyanine green (ICG),**
- ❖ - Surgical morbidity and mortality,
- ❖ - Longitudinal and other dimensions of health related Quality of life.
- ❖ - Positive and negative predictive values of SLN biopsy.
- ❖ - Overall survival.
- ❖ - Recurrence free survival.
- ❖
- ❖ A cost analysis will be developed in some countries.
- ❖ A tumor bank will be built by collection of cervical specimen. A translational research will be performed in a subsequent study to investigate predictors of recurrence in low risk patients.

Schema



Randomized study
Surgical & pathological quality assurance



❖ Inclusion criteria:

- Squamous or adenocarcinoma of the cervix (proven by biopsy or cone biopsy)
- Stage Ia1 with lymphovascular emboli to IIa1 (clinical stage)
- Maximum diameter ≤ 40 mm on MRI
- No suspicious node on pelvic and abdominal MRI (small axis $\geq 8-10$ mm and morphologic criteria)
- Informed consent given

❖ Exclusion criteria:

- Age < 18 years
- Pregnancy
- Previous pelvic or abdominal cancer
- Previous chemo and/or radiation therapy for the cervical cancer
- Allergy to blue dye, isotope or Indocyanine green

Statistics

❖ 1-DFS

- ❖ With a 3 years-disease free survival of 85% to demonstrate a non-inferiority of SLN biopsy vs SLN biopsy + lymphadenectomy with a non-inferiority margin of 5% (80 vs 85%, HR = 1.373). With a unilateral alpha error of 5%, and a power of 80%, 900 patients in 3 years, with 4 years of follow-up should be included to observe the required 219 DFS events. An interim analysis is planned when at least 110 events will be observed to reject H0 or H1 using O'Brien Fleming and alpha spending function.

❖ 2-HRQoL

- ❖ We target 3 HRQoL dimensions global health, pain and physical functioning of EORTC QLQC 30 compared at 3 years.
- ❖ To demonstrate a superiority of at least one of the 3 targeted dimensions without significant deterioration in at least one with a minimal important difference in mean score of at least 5 points (SD: 20), and a bilateral alpha type one error of 0.015 (Bonferroni adjustment it would be required to have 815 patients with available HRQoL scores to reach 85% statistical power.

❖ **900 patients have to be randomized**

❖ **An international collaboration is requested**



Participating & interested groups

- AGO
 - NOGGO
 - DGOG
 - G-GOC
 - MITO
 - MANGO
 - NCIC
 - And....
-
- Patients association « 1000 femmes – 1000 vies »



Thank you

- bvotan@arcagy.org
- fabrice.lecuru@aphp.fr
- franck.bonnetain@univ-fcomte.fr

GYNECOLOGIC
CANCER INTERGROUP

An Organization of International Cooperative
Groups for Clinical Trials in Gynecologic Cancers

